AdvaMed Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech  

WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally. 

“We thank President Trump for this important progress, including a de-escalation from potentially higher tariffs and continued access to the rare earth elements critical for medtech manufacturing,” said Scott Whitaker, AdvaMed president and CEO. “Medtech is critical to making Americans healthy again, and we welcome policy support to continue our mission of saving and improving lives.

“Medtech innovators need certainty in tariffs policy to continue their manufacturing, research and development, and investment, which all occurs predominately in the United States. They need reliable supplies for their often-complex products. Steps toward meeting these core needs bring confidence to U.S. medtech companies to continue increasing their already large, well-established footprint in the United States. The U.S. medtech industry is a uniquely American success story.” 

AdvaMed has sought tariff relief on behalf of its more than 600 member companies since the outset of tariff deliberations. Medtech traditionally has been exempt from tariffs for humanitarian reasons. Medtech companies, often small businesses and start-ups, support three million jobs nationwide with more than $250 billion in annual output through 16,000 manufacturing facilities across all 50 states. 

Last month, AdvaMed detailed U.S. medtech’s role as a global leader in innovation, jobs, and manufacturing in its response to the U.S. Department of Commerce Section 232 investigation of medtech imports as a national security concern. AdvaMed pressed for tariffs relief and outlined policy recommendations to further strengthen U.S.-led medtech.

For more on U.S.-led medtech, please see our fact sheet and visit advamed.org/medtechsaves/.

###